Therapeutic Expertise
Ophthalmology
Our ophthalmology team runs trials across retinal, glaucoma and ocular surface disease, supported by a central reading room and standardised imaging that keep visual endpoints reliable across sites.
Ophthalmic endpoints — BCVA, OCT, visual fields and imaging-based measures — are exacting and reader-dependent. We provide centralised imaging review, standardised acquisition protocols and physician oversight so that efficacy signals are robust and regulator-ready.
Addressing common pain points in ophthalmology clinical trials
Imaging standardisation across sites
OCT and fundus imaging vary by device and operator, threatening endpoint consistency.
Our independent, blinded reading centre standardises acquisition and grading across all sites.
Reliable visual function endpoints
Visual acuity and field testing are sensitive to protocol and rater variation.
We certify assessors and enforce standardised testing protocols to protect endpoint integrity.
Recruiting well-defined ocular populations
Retinal and glaucoma trials require precise disease staging for eligibility.
We use imaging-driven screening to ensure the right patients are enrolled efficiently.
Resources
Ophthalmology clinical trial resources
Age-related Macular Degeneration Clinical Trials
Design and endpoints in AMD research.
Innovations in Glaucoma Treatment
Advances and trial considerations in glaucoma.
Evidence & insights
Ophthalmology white papers
Open-access reports from our physicians and data science teams — free, no sign-in.
The iNGENū CRO difference
Australian expertise, direct FDA submission
We uniquely combine Australian expertise with direct FDA submission capabilities, offering a streamlined path for sponsors to achieve global approval. Trial data from Australia can be submitted directly to the FDA via our E-Gateway, eliminating the need for third-party intermediaries.
iNGENū takes a highly strategic and disciplined approach to clinical research, ensuring every dollar is directed toward generating meaningful outcomes — eliminating unnecessary costs while maintaining the highest scientific and regulatory standards across the Asia-Pacific region.
“We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug — medical writing, project management, clinical data management and full end-to-end execution and monitoring. We have been particularly impressed by the out-of-the-box creative solutions to speed up and reduce overheads during this clinical trial.”
Giles MossChief Executive Officer
Ready to discuss your Ophthalmology clinical trial?
Talk to our team about how iNGENū CRO can accelerate your research.
Request a proposal